Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
  • A61L27/60—Materials for use in artificial skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
  • A61K8/73—Polysaccharides
  • A61K8/736—Chitin; Chitosan; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
  • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
  • A61F2/0059—Cosmetic or alloplastic implants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
  • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
  • A61K31/716—Glucans
  • A61K31/722—Chitin, chitosan
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
  • A61K8/04—Dispersions; Emulsions
  • A61K8/042—Gels
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
  • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
  • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4841—Filling excipients; Inactive ingredients
  • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/14—Macromolecular materials
  • A61L27/20—Polysaccharides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/14—Macromolecular materials
  • A61L27/26—Mixtures of macromolecular compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
  • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
  • A61L27/3633—Extracellular matrix [ECM]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
  • A61L27/52—Hydrogels or hydrocolloids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
  • A61L27/54—Biologically active materials, e.g. therapeutic substances
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
  • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
  • A61L27/58—Materials at least partially resorbable by the body
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/08—Anti-ageing preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
  • A61K2800/91—Injection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
  • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
  • A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
  • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
  • A61L2300/63—Crystals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2400/00—Materials characterised by their function or physical properties
  • A61L2400/06—Flowable or injectable implant compositions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
  • A61L2430/00—Materials or treatment for tissue regeneration
  • A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids

Definitions

• the present invention relates to the technical field of cosmetic fillers, biomaterials, skin physiological reconstruction materials, regenerative medicine, reconstructive surgery, especially anti-aging skin, in humans or possibly animals.
• the present invention relates to an aqueous chitosan composition for specifically targeting adipocytes.
• the invention also relates to such compositions for use as a dermatological composition, a cosmetic, or as a medical device, advantageously as a bioabsorbable implant.
• Various injectable fillers, especially in humans, are already known.
• Collagen has long been the product of choice as a filling product for the face, especially for filling wrinkles and fine lines or even for lip repointing.
• hyaluronic acids since the placing on the market of hyaluronic acids, the latter are the most used.
• the direct injection of hyaluronic acid has the advantage of having an immediate filling effect associated with a minor inflammatory reaction, because of its biocompatibility.
• its implantation is associated with a rapid biodegradation which makes the product unsatisfactory, even if the life of the product injected could be prolonged through the use of crosslinked hyaluronic acids.
• PLA polylactic acid
• a polymer whose biodegradation is slower than the others natural polymers, such as collagen or hyaluronic acid It is estimated that the filling persists until two years after the injection.
• These products have been marketed in particular under the name of New-Fill® (or Sculptra®).
• New-Fill® or Sculptra®
• the main disadvantage of this technology is that the filling effect is visible only after a period of eight weeks, which does not bring complete satisfaction to the patient.
• the fibrosis observed during the use of non-degradable products appeared of great interest in terms of long-term aesthetic effect, and this is how "semi-permanent" filling products were developed.
• Atlean® product which offers a dispersion of particles of TCP (tricalcium phosphate) in hyaluronic acid
• Radiesse® product which provides a dispersion of calcium hydroxyapatite particles in a carboxymethyl cellulose gel.
• the vector gel ensures the aesthetic effect of immediate filling, while the particles gradually generate a fibrosis that guarantees the long-term effect.
• the interest of these products, besides this double mechanism of action (mechanical and inductive tissue) is that they are finally completely resorbed.
• chitosan is another molecule that has found its interest in the field. Indeed, because of its unique chemical and biomimetic structure, chitosan behaves vis-à-vis the organism as a "decoy" of the biological environment (Montembault A., Tahiri K., Korwin-Zmijowska C., X , Knight, M. Corvol, A.Domard, Biochemistry, 88 (2006), 551-64): on the one hand, it is sufficiently “recognized” not to induce a dangerous inflammatory reaction, and on the other hand sufficiently “ unknown "to not be degraded too quickly.
• the molecule consists in fact of a succession of N-acetyl-D-glucosamine and D-glucosamine units, the former being a component of extracellular matrix molecules (this residue is found in hyaluronic acid for example), and the latter being completely absent from it, chitosan is therefore more difficult to degrade from a biological point of view.
• chitosan is known in the literature for stimulating certain immune cells, such as macrophages, which produce in its presence an increased amount of growth factors. These growth factors are biological mediators that promote the production of extracellular matrix and the proliferation of fibroblasts, cells that produce collagen fibers.
• chitosan promotes the synthesis of fibrous tissue, which allows a "biological" filling in the long term, including a filling of cutaneous defects or cavities of the human body or face, such as wrinkles.
• the Applicant had previously attached to chitosan for the above application, which was the subject of a patent application WO 2013/07964.
• the adipocytes subjected to this treatment proliferate and swell in a controlled manner, and allow the skin to firm up by filling wrinkles and fine lines or to allow the filling of default skin (s) or the volumetric reconstruction of tissues.
• This observation led the Applicant to focus more particularly on the adipocytes.
• several points were identified by the Applicant. He first noticed that too high concentration of chitosan, without removing the other benefits, could nevertheless be toxic to the adipocytes. It has also been observed by the Applicant that the presence of at least one compound of the extracellular matrix in the aqueous composition makes it possible to increase the fatty acid capture of the adipocytes.
• the chitosan composition according to the present invention induces the synthesis of collagen fibers.
• the addition of at least one component of the extracellular matrix (or a substituent) makes it possible to potentiate the action of chitosan.
• the Applicant proposes aqueous compositions having a direct action on the adipocytes at (sub) -cutaneous level to add an original technical solution to the art in the field of skin treatment and reconstructive surgery.
• the object of the present invention relates to an aqueous composition of chitosan comprising between 0.1 and 5% by weight of chitosan relative to the total weight of the composition, for its use in increasing the volume and / or the number of adipocytes.
• the increase in the volume and / or the number of adipocytes thus obtained makes it possible to use in the treatment or fight against aging of the skin, for filling skin defects such as wrinkles or for repairing or repairing the skin. reconstruction of cutaneous or subcutaneous tissues.
• the present invention relates to the use of an aqueous composition of chitosan comprising between 0.1 and 5% by weight of chitosan relative to the total weight of the composition, to increase the volume and / or the number of adipocytes.
• this use is preferably cosmetic, and non-therapeutic.
• the aqueous composition according to the present invention can be used for filling the cavities of the body or face, such as wrinkles or fine lines, for creating or increasing volumes of the face or the human body, or for scarring of the skin.
• Adipocytes are commonly known to be animal cells present in adipose tissue, and specialized in storing fat.
• adipocytes are also included in the visceral tissue and in the hypodermis which is the deep layer of the skin, containing more or less adipose tissue, serving as an interface between the dermis and the mobile structures below him (organs, muscles etc.).
• the subcutaneous adipocytes are located at a variable depth of the surface of the skin, varying from a few millimeters to several centimeters deep.
• adipocytes in the context of the present invention, it is considered human adipocytes.
• the object of the present invention further relates to an aqueous composition as described herein, for its use as a dermatological composition or as a medical device, advantageously as a bioabsorbable or partially bioabsorbable implant for increasing the volume and / or the number of adipocytes.
• bioabsorbable or “bioresorption” is meant biodegradation which results in total or substantially total degradation of the injected product.
• the aqueous composition has good biocompatibility and is bioabsorbable.
• the product according to the invention has a longer bioresorption time than products based on hyaluronic acid of the crosslinked hyaluronic acid type, for a prolonged effect, such as a prolonged filling effect.
• the present invention also relates to the use of at least one extracellular matrix compound, and / or at least one substitute of the extracellular matrix for reducing the toxicity to adipocytes of an aqueous composition of chitosan comprising between 0.1 and 5% by weight of chitosan relative to the total weight of the composition.
• the present invention relates to an aqueous composition of chitosan.
• aqueous composition is meant a composition comprising at least 1% by weight of water, preferably at least 50% by weight of water, more preferably at least 80% by weight of water.
• the percentages, generally for the present invention, when they are not specified, correspond to percentages by weight relative to the total weight of the composition under consideration.
• the aqueous chitosan composition according to the invention has a pH of less than 8.5, advantageously between 4 and 7.6.
• the pH of said solution is greater than or equal to 5.5, advantageously between 5.5 and 7.5, preferably between 6.2 and 6.8.
• the aqueous composition according to the present invention is advantageously an aqueous solution of chitosan, an aqueous gelling solution of chitosan or an aqueous gel of chitosan.
• solution is meant in the sense of the present invention a composition in liquid form, as opposed to a gelled composition.
• a solution has a liquid phase containing at least two chemical species.
• An "aqueous solution” comprises at least 1% by weight of water, preferably at least 50% by weight of water, still more preferably at least 80% by weight of water.
• an aqueous solution according to the present invention mainly comprises water, with possibly other compounds.
• the aqueous solution according to the present invention is an aqueous chitosan solution.
• the aqueous solution according to the present invention is a homogeneous aqueous solution of chitosan.
• the term "homogeneous aqueous solution of chitosan” means that all the chitosan polymer is solubilized and that the solution does not contain solid particles of chitosan suspended in the liquid phase.
• the aqueous solution thus formed comprises at least water in the proportions mentioned above and chitosan with optionally other compounds.
• the homogeneous aqueous chitosan solution according to the present invention is typically transparent.
• aqueous chitosan composition according to the present invention can be used to form a gel.
• gel it may be admitted according to the present invention that it is a body having a conservation modulus greater than the loss modulus (see HH Winter, F. Chambon Analysis of linear viscoelasticity of a crosslinking polymer at the gel point J. Rheol., 30 (1986), pp. 367-382).
• the stability and integrity of this body are maintained either by non-covalent interactions (physical gel) or by covalent chemical crosslinking (chemical gel).
• composition or aqueous “gelling" solution of chitosan it is understood in the context of the present invention a composition or an aqueous solution of chitosan as defined above, capable of providing an aqueous gel of chitosan, in particular when is injected into the biological medium.
• an object according to the present invention relates to a gel obtained from the composition or aqueous solution as described above. In a particular embodiment of the present invention, this gel is formed before incorporation into a composition as described herein.
• this gel is formed after incorporation into a composition. This can be done by varying pH (changing to a physiological pH, i.e. between 6.8 and 7.8, preferably at a pH of 7.4 + 0.2).
• the aqueous composition according to the invention is injectable in the human or animal body, typically by intradermal, subcutaneous or intraperitoneal injection.
• the composition may be packaged in a syringe such as a sterile syringe.
• the aqueous composition has a suitable viscosity to ensure good syringability (satisfactory flow through a needle in a syringe) and ease of injection.
• the aqueous composition according to the invention is sterilized before injection, for example by autoclaving.
• the composition according to the present invention can be formulated to be administered by intradermal injection, subcutaneous injection or intraperitoneal injection.
• An intradermal injection is the administration of a compound into the dermis of the skin, located just below the epidermis.
• a subcutaneous injection is to introduce a needle into the subcutaneous layer of the skin, to inject a molecule of interest.
• An intraperitoneal injection is located beyond the peritoneum in the abdominal cavity, i.e. in the adipo-visceral tissue.
• the aqueous composition according to the present invention is comprised or consists of an implant for treating cutaneous depressions. It may be skin depressions of small volumes (ie equal to or less than 5 mL equivalent to about 5 grams depending on the density of the composition) or which can not be filled by injections of small volumes. This is the case, for example, of the filling of the removal of an organ or tissue following an accident or a disease (eg mammoplasty, acute lipodystrophy, acute lipoatrophy, polio-filling treatment), in reconstructive surgery.
• a disease eg mammoplasty, acute lipodystrophy, acute lipoatrophy, polio-filling treatment
• the chitosan composition has a long resorption time once injected, typically from a few weeks to several months, for example of the order of 3 or 4 weeks up to 12 to 18 months.
• the product or biomaterial consisting of or containing the aqueous composition according to the invention benefits from the bacteriological and fungistatic character of chitosan, well known in the world of the food industry and healing dressings. These properties facilitate the preservation of the product and help to reduce the risk of infection related to injection or delayed inflammatory phenomena for other products as mentioned above.
• chitosan Faced with natural molecules (collagen, hyaluronic acid) used to date for the filling of depression or volume reconstruction (eg wrinkles, fine lines, mamoplasty or lipodystrophy), chitosan is the only one to have such properties. Furthermore, the product or biomaterial consisting of or containing the aqueous composition according to the invention provides effective biological filling advantageously immediate. In addition, chitosan can promote the synthesis of collagen and allow a filling of skin defects, such as wrinkles, by stimulating natural mechanisms. In addition, the aqueous composition according to the present invention is advantageously capable of forming crystalline particles of chitosan after injection. Indeed, in this way the effects as described previously in WO201307964 are cumulative effects related to the present invention.
• composition according to the invention comprises at least one chitosan.
• Chitosan is an amino-polysaccaharide generally obtained by N-deacetylation of chitin, a polysaccharide as common in biomass as cellulose. Chitin is particularly present in the cuticles of arthropods, the endo skeleton of cephalopods, the cell walls of fungi, yeasts or algae.
• chitosan is a natural product which comes from an animal source, for example crustaceans of the crab, shrimp or squid type, or from a vegetable source, such as mushrooms or seaweed.
• Chitosan and chitin are linear copolymers of 2-acetamido-2-desoxy-D-glucan and 2-amino-2-desoxy-D-glucan, respectively. More commonly known are N-acetyl-D-glucosamine (GlcNAc) and D-Glucosamine (GlcN) units, linked by ⁇ (1 ⁇ 4) glycosidic linkages. Chitin and chitosan are differentiated by the molar fraction (expressed in%) of the GlcNAc units present in the copolymer, also called degree of acetylation (DA).
• DA degree of acetylation
• the DA is calculated using the formula
• the AD can thus be determined according to current standards (ie, "Standard Guide for Characterization and Testing of Chitosan Salts as Starting Materials Intended for Use in Biomedical and Tissue-Engineered Medical Product Applications, Book of Standards Volume: Volume 13.01; -F2103 ").
• the chitosan has a degree of acetylation (DA) of less than 30%, even more advantageously less than or equal to 20%, for example less than 15%.
• DA degree of acetylation
• the chitosan according to the invention has a degree of acetylation DA less than or equal to 15%, advantageously less than 10%, more preferably less than 8%, and still advantageously less than 5%.
• the chitosan according to the invention has a degree of acetylation DA less than or equal to 4%, advantageously less than 3%, more preferably less than 2%, still more preferably less than 1%.
• the chitosan according to the invention has a degree of acetylation DA of between 1 and 20%, advantageously between 2 and 15%, advantageously between 3 and 10%, for example between 4 and 8%.
• the degree of acetylation is preferably measured according to the method described in the publication "Physico-chemical studies of the gelation of chitosan in a hydroalcoholic medium" A. MONTEMBAULT, C. VITON, A. DOMARD Biomaterials, 26 (8), 933 -943, 2005).
• the chitosan used in the solutions of the invention preferably has a mass average molecular weight (determined before sterilization according to the method described in "Physico-chemical studies of the gelation of chitosan in a hydroalcoholic medium" A. MONTEMBAULT, C VITON, A. DOMARD Biomaterials, 26 (8), 933-943, 2005) between 100,000 and 1,500,000 g / mol, advantageously between 200,000 and 1,000,000 g / mol, more preferably between 250,000 and 500,000. 000 g / mol, and even more preferably between 300 000 and 400 000 g / mol.
• chitosan typically has a weight average molecular weight of between 80,000 and 1,000,000 g / mol, and advantageously between 120,000 and 300,000 g / mol.
• a chitosan with a molar mass of between 100,000 and 1,000,000 g.mol -1 may also be characterized by its viscosity (typically at a concentration of 1% in a 1% aqueous solution of acetic acid at 25 ° C).
• the molar mass of chitosan can also be defined by a viscosity of between 5 Pa.s and 20 Pa.s.
• the viscosity of the composition is measured at 25 ° C. using a DHR1 rheometer (TA Industries) and a planar geometry of 40 mm in a dynamic mode with an applied shear rate of 0.01 to 1 s -1 .
• the chitosan used in the solutions according to the invention is not chemically modified, and in particular, is not grafted to promote its solubility in aqueous solution at near neutral pH ( between 6.2 and 7.2) It is distinguished in this sense chitosan implemented in the application WO03 / 042250 or the application JP-H02-69502, in the publication "Synthesis and char act of the sugar-bearing chitosan derivatives: aqueous solubility and biodegradability ", Jae Hyung Park et al., Biomacromolecules 2003, 4, 1087-1091, and in the publication" Water solubility of N-acetylated chitosans as a function of pH: ejfect
• this other chitosan may be in the form of crosslinked chitosan particles.
• the composition according to the invention is free of chitosan having a high degree of acetylation, in particular greater than 20% and more specifically between 40 and 60%.
• the composition according to the invention is free of an additional oligomer, in particular a chitosan oligomer, of low average molecular weight, especially less than 20,000 g / mol.
• aqueous composition of chitosan comprises less than 1% by weight of these compounds, in particular less than 0 , 5% by weight, and more preferably, does not contain these compounds.
• the aqueous composition according to the present invention may comprise at least one chitosan dispersing agent.
• This type of dispersing agent is very well known in the art and may for example be selected from mannitol, glycerol, sorbitol and mixtures thereof.
• composition according to the invention may also comprise a pH buffer to set at physiological pH.
• a pH buffer to set at physiological pH.
• Any pH buffer commonly used for this purpose can be used, for example PBS ("Phosphate Buffer Saline” - phosphate buffer saline solution).
• the composition according to the invention comprises a salt such as sodium chloride or potassium chloride, or any other excipent acceptable advantageously to adjust the osmolarity of the composition.
• a salt such as sodium chloride, or potassium, can be interesting to get a solution isotonic.
• the composition may further comprise at least one compound having a recognized therapeutic activity.
• aqueous chitosan composition according to the present invention may further comprise at least one pharmaceutically, dermatologically and / or cosmetically acceptable compound or excipient.
• composition according to the present invention may comprise at least one active compound such as an analgesic compound, a local anesthetic, such as lidocaine, mepivacaine, bupivacaine or ropivacaine, an angiogenic compound, or an active compound of the growth factor type. or bioactive oligosaccharide.
• active compound such as an analgesic compound, a local anesthetic, such as lidocaine, mepivacaine, bupivacaine or ropivacaine, an angiogenic compound, or an active compound of the growth factor type. or bioactive oligosaccharide.
• the composition according to the invention may comprise a compound or a substituent of the extracellular matrix.
• Extracellular matrix typically refers to the set of extracellular macromolecules of connective tissue and other tissues.
• a compound of the extracellular matrix according to the present invention is advantageously an organic polymer, for example of a size greater than 1000 Daltons (Da), or even greater than 5000 Da.
• the organic polymers of the extracellular matrix according to the present invention may be of a proteinic, glucosidic, proteoglucosic or glucoproteic nature.
• the organic polymers of the extracellular matrix may be collagen, hyaluronic acid or fibronectin.
• extracellular matrix substituent is a non-ubiquitous compound (i.e. not found naturally in humans for this function) to fulfill the role of extracellular matrix.
• This type of compound is known in the art (Jayakumar, R., Menon, D., Manzoor, K., Nair, SV, & Tamura, H. (2010) Biomedical applications of chitin and chitosan based nanomaterials- A short Carbohydrate Polymers, 82 (2), 227-232).
• the compound of the extracellular matrix is preferably selected from proteins, glycosaminoglycans and mixtures thereof.
• the proteins and their glycosylated derivatives may preferably be selected from collagen, elastin, fibronectin, laminin or mixtures thereof.
• glycosaminoglycans may preferably be chosen from hyaluronic acid, chondroitin sulfate, heparan sulfate, keratan sulfate or a mixture of at least two of these glycosaminoglycans.
• the compound of the extracellular matrix is chosen from proteins and their glycosylated derivatives, preferably from collagen, fibronectin, and a mixture of collagen and fibronectin.
• the substituent of the extracellular matrix may for its part be chosen from carboxymethylcellulose, chitosan ester, chitin ester and the mixture of at least two substituents of the extracellular matrix.
• composition according to the invention when the composition according to the invention comprises a compound or a substituent of the extracellular matrix, it is free of an additional oligomer, in particular a chitosan oligomer of low average molecular weight, in particular less than 20 000 g / mol.
• the aqueous composition according to the present invention preferably contains less than 5% by weight, relative to the total weight of the composition of at least one compound of the extracellular matrix and / or at least one substitute of the extracellular matrix, in particular between 0.01 and 5% by weight, advantageously between 0.1 and 4% by weight, more advantageously between 0.2 and 3% by weight, still more advantageously between 0.3 and 2% by weight, or even between 0, 5 and 1% by weight.
• the homogeneous aqueous composition of chitosan according to the present invention when it comprises a compound of the extracellular matrix and / or a substitute of the extracellular matrix, preferably contains a quantity of chitosan less than or equal to 5% by weight with respect to total weight of the aqueous composition, advantageously less than or equal to 4% by weight relative to the total weight of the aqueous composition, less than or equal to 3% by weight relative to the total weight of the aqueous composition, still less than or equal to 2% by weight relative to the total weight of the aqueous composition.
• the homogeneous aqueous chitosan composition according to the present invention when it comprises a compound of the extracellular matrix and / or a substitute of the extracellular matrix, contains between 0.1 and 5, advantageously between 0.5 and 3.5, in especially between 1 and 2, by weight of chitosan, relative to the total weight of the aqueous composition. More preferably, the homogeneous aqueous chitosan composition according to the present invention, when it comprises a compound of the extracellular matrix and / or a substitute of the extracellular matrix, contains between 1.5 and 2, advantageously between 1.6 and 1.9, in particular between 1.7 and 1.8, by weight of chitosan, relative to the total weight of the aqueous composition.
• the homogeneous aqueous chitosan composition according to the present invention when it comprises a compound of the extracellular matrix and / or a substitute of the extracellular matrix, contains less than 2, advantageously less than 1.9, in particular less than 1.8, more preferably less than 1.7, still more preferably less than 1.6, by weight of chitosan, based on the total weight of the aqueous composition.
• the aqueous composition of chitosan according to the invention can in particular be prepared by the following successive steps: a. dissolving the chitosan in water by adding acid such as a weak acid, said weak acid being advantageously chosen from the group consisting of acetic acid, glycolic acid, lactic acid, acid glutamic acid, or such as a strong acid, said strong acid being advantageously hydrochloric acid, and mixtures thereof, b. the addition, if appropriate, of at least one compound and / or a substitute of the extracellular matrix and c. the optional readjustment of the pH to obtain an aqueous composition having a pH of less than 8.5.
• acid such as a weak acid
• said weak acid being advantageously chosen from the group consisting of acetic acid, glycolic acid, lactic acid, acid glutamic acid, or such as a strong acid, said strong acid being advantageously hydrochloric acid, and mixtures thereof
• the gelled aqueous chitosan composition may be dispersed by adding a dispersing agent as presented above, optionally with a step of mechanical fragmentation of the gel of said composition.
• aqueous chitosan aqueous chitosan.
• the composition obtained can in all cases be a suspension or a solution, which can be administered for example by injection, preferably gelling.
• the aqueous composition of the present invention obtainable by the steps described above.
• the pH control of the solutions is very important to avoid, on the one hand, the acid necrosis of the tissues after injection as explained above, and also to protect the compositions from hydrolysis and the degradation of chitosan if one implements sterilization (for example by autoclaving at 121 ° C for 15 minutes).
• the pH is readjusted if necessary with a compound such as sodium bicarbonate or PBS buffer, typically in reduced amounts.
• the pH value is advantageously controlled by a pH meter.
• the pH adjustment can preferably be carried out very gradually by dialysis.
• Dialysis is a process of membrane separation of molecules or ions in solution.
• the aqueous chitosan solution according to the invention can be dialyzed against a buffer solution having a pH equal to the desired final pH for the chitosan solution (target pH), that is to say at least greater than 6.2, advantageously between 6.2 and 7.2, preferably between 6.25 and 7.1.
• target pH desired final pH for the chitosan solution
• target pH target pH
• the buffer solution has a pH greater than the gelation pH of the solution (eg 7.5)
• dialysis should then be monitored to avoid gelation of the solution.
• the buffer solution may, for example, be a saline solution of phosphate buffer (PBS, TBS, PBS-lactic acid), tris (tris (hydroxymethyl) methylamine), 4-2-hydroxyethyl-1-piperazineethanesulfonic acid (HEPES), 2- ⁇ [tris (hydroxymethyl) methyl] amino ⁇ ethanesulfonic acid (TES), 3- (N-morpholino) propanesulfonic acid (MOPS), piperazine-N, N'-bis (2-ethanesulfonic acid)), MES ( 2- (N-morpholino) ethanesulfonic acid (PIPES), sodium chloride (NaCl).
• PBS phosphate buffer
• TBS PBS-lactic acid
• tris tris (tris (hydroxymethyl) methylamine
• HEPES 4-2-hydroxyethyl-1-piperazineethanesulfonic acid
• TES 2- ⁇ [tris (hydroxymethyl) methyl] amino ⁇ ethane
• the buffer solution is a solution of phosphate buffer PBS (phosphate buffered saline) composed of an acid salt NaH 2 PO 4 , a "basic” salt. Na 2 HPO 4 and NaCl.
• PBS phosphate buffered saline
• the buffer is physiologically acceptable, that is to say that it presents no risk of intolerance or toxicity during injection into the tissues of the injectable solution according to the invention.
• the buffer is preferably different from glycerophosphate, and in particular ⁇ -glycerophosphate which, although not irritating to the skin, causes calcification problems when it is injected into the tissues.
• the dialysis can be performed statically in a single bath against a buffer solution as described above. When the dialysis is performed statically in a single bath against a buffer solution, it is preferable that said buffer solution has a pH equal to the desired final pH for the chitosan solution (target pH), for example between 6.5 and 6. 9.
• the dialysis can be performed statically in several successive baths against buffer solutions having different pHs closer and closer to the desired final pH for the chitosan solution (target pH).
• the dialysis is carried out dynamically, that is to say by continuously circulating at least one solution allowing the gradual increase in pH through one or more dialysis bags constituted a dialysis membrane containing the aqueous solution of chitosan.
• This type of dialysis is for example described in patent application WO 2016/170284 of the Applicant.
• the chitosan is dissolved in water using a strong acid of the hydrochloric acid type.
• the pH is readjusted with a compound of the sodium bicarbonate or ammonium or PBS type, for example, and / or a base of the NaOH or KOH type for example (always by controlling the pH so that it is remains less than 8.5, preferably less than 6.9).
• the acid is added in an amount necessary for the dissolution of chitosan.
• An excess of acid can thus be used for certain chitosans, for example chitosans which are difficult to solubilize with the strictly necessary amount of acid, and then the chitosan is reprecipitated with ammonia for example. After a series of washes to remove excess ammonia and salts, the chitosan can be lyophilized to recover the dry matter. This will then be easier to solubilize.
• the acid is added in an amount at least necessary for the dissolution of chitosan, such as the stoichiometric amount strictly necessary for the protonation of the NH sites. 2 .
• the pH of the aqueous composition according to the present invention is less than 8.5, and is typically between 4 and 7.6.
• chitosan is solubilized in aqueous solution, such as water, in a acidic environment in the above-mentioned pH ranges, advantageously by protonation of the amine groups of chitosan. These pH ranges have been chosen in particular to maximize the stability of the aqueous composition according to the invention.
• the object of the present invention further relates to an aqueous composition, as described above, characterized in that said composition is liquid, in gel form or obtained after dispersion of said aqueous chitosan composition in a vehicle dermatologically and / or cosmetically acceptable.
• dermatologically and / or cosmetically acceptable vehicle it is within the scope of the present invention any dermatologically and / or cosmetically acceptable excipient, or any dermatologically and / or cosmetically acceptable matrix or device, allowing the administration of the aqueous composition. according to the present invention.
• an aqueous composition as described herein is included in a composition with a possibly a pharmaceutically, dermatologically, and / or cosmetically acceptable compound or excipient, its use as a dermatological composition or as a medical device, advantageously as a bioresorbable or partially bioabsorbable implant may to be administered at the following dosages.
• the amount of chitosan may be from 0.1 to 5% by weight, preferably from 1 to 2% by weight, more preferably from 1.1 to 1.9% by weight, still more preferably from 1.2 to 1, 8% by weight, and even more advantageously between 1.3 and 1.7% by weight or between 1.4 and 1.6% by weight, for example at 1.5% ⁇ 0.05% by weight of chitosan relative to the total amount of aqueous composition administered.
• the quantity of composition or aqueous composition administered in a single dose is between 0.01 and 20 grams per injection, advantageously between 0.05 and 10 grams per injection, more advantageously between 0.1 and 5 grams per injection, more advantageously between 0.4 and 1 gram per injection, for example 0.7 grams ⁇ 0.1 gram per injection.
• the number of injections can vary from 1 to 20 times in the most extreme cases. More routinely, this number of injection is less than 5 times to effectively fill cavities with a volume less than 50 ml (therefore at physiological temperature).
• the amounts of composition according to the present invention that can be injected and / or implanted can be added to equal masses or less than 500 grams, more commonly equal or less than 350 grams, still more commonly equal to or less than 200 grams, or equal to or less than 100 grams.
• the density of the aqueous composition administered is between 0.9 and 1.2 at 25 ° C (thus before administration).
• the cosmetic use according to the present invention is de facto defined as not being invasive in the administration of the composition according to the present invention. This precludes any surgical procedure. Nevertheless, the cosmetic use according to the present invention can be carried out with small syringes and needles, in an act comparable to the application of a tattoo.
• the quantities injected composition according to the present invention greater than 5 grams per injection are excluded in the context of a cosmetic use. In this context, the number of injections is arbitrarily limited to 5 times at most for a total amount injected of 10 grams.
• the amount of aqueous composition administered in a single dose may be between 0.001 and 1 gram per cm 2 of skin area, advantageously between 0.01 and 0.5 gram per cm 2 of skin area.
• the density of the aqueous composition administered is from 0.9 to 1.2 at 25 ° C.
• Figure 1A and 1B Effect on the proliferation of 3T3L1.
• Figure 1 shows that for all concentrations, the 3T3L1 cells are able to proliferate and reach confluency in 5 days, although two days after seeding, the morphology of the cells suggests an aggressive medium, even toxic for the 2% condition.
• Figure 1B specifies where on the experimental images obtained could be seen the signal corresponding to the Adipored (green experimentally, vs. Red for Hoecht).
• FIGS. 2A, 2B and 2C show the influence of the chitosan concentration on the storage of oleic acid by 3T3L1 cells during adipocyte differentiation.
• AdipoRed labeling (Fig 2A) shows an accumulation of fatty acids when the cells are in the presence of 0.5%, 0.75% and 1% chitosan with respect to conditions containing no chitosan.
• Figure 2B specifies where on the experimental images obtained could be seen the signal corresponding to the Adipored (green experimentally). Quantification of this accumulation (FIG 2C) demonstrates that it is maximal when the cells are cultured in the presence of 0.5% chitosan.
• Figure 3 This figure shows a distribution of lipid droplets (n> 10,000) of 3T3L1 exposed a chitosan composition and a formulation comprising chitosan combined with collagen and fibronectin.
• Figure 3 shows that (Col 2 + FNl) + Chitosan2%) are the best formulations to increase the number and average size (volume) of lipid droplets.
• chitosan 4 g are stirred in 95 g of saline solution containing 150 mM NaCl (equivalent to 300 mOsmol.L 1 ). Once the chitosan is completely dispersed, 1 g of acetic acid is added. Stirring is maintained until complete dissolution of the chitosan. A clear solution of chitosan concentrated at 4% is then obtained with a pH which can be between 3 and 4.5 depending on the origin of the chitosan.
• a solution of 4% chitosan (w / w) is obtained in a saline solution (NaCl at 300 mOsmol.L -1 ) containing 1% (w / w) of acetic acid.
• the pH of the chitosan acid solution is raised to between 6 and 6.5. This step is carried out by dialysis against a PBS buffer having a pH of between 6.5 and 7. During this step, the swelling of the chitosan solution is controlled to reach a final concentration of 3% (w / w) (swelling rate). 33%).
• Chitosan solutions are usually sterilized (121 ° C for 15 min in an autoclave) to be stored before use. This solution is dialyzed to obtain a pH close to 6 and a concentration of 3% (w / w).
• the 3% chitosan solution can be diluted in 150 mM NaCl + 1% acetic acid salt solution to lower concentrations.
• the solutions obtained can gel in the presence of the physiological medium or a culture medium.
• chitosan 4 g are stirred in 95 g of saline solution containing 150 mM NaCl (equivalent to 300 mOsmol.L -1 ) Once the chitosan has been completely dispersed, 1 g of acetic acid is added. until complete dissolution of the chitosan A clear solution of chitosan concentrated to 4% is then obtained with a pH which can be between 3 and 4.5 depending on the origin of the chitosan.
• a solution of 4% chitosan (w / w) is obtained in a saline solution (NaCl at 300 mOsmol.L -1 ) containing 1% (w / w) of acetic acid.
• This stock solution (4%) was then diluted in a saline solution (NaCl 300 mOsmol.L "l) containing 1% (w / w) acetic acid in different concentrations ranging from 4% to 0.1%.
• a saline solution NaCl 300 mOsmol.L "l) containing 1% (w / w) acetic acid in different concentrations ranging from 4% to 0.1%.
• Each solution is then dialyzed against a PBS buffer having a pH between 6.5 and 7. The swelling rate is measured to control the final concentrations of each solution.
• the dialysis is stopped when the pH of the solutions is between 6.0 and 7.4. sterilized by autoclave (121 ° C. for 15 minutes)
• the solutions are used as they are without any other form of dilution, which preserves their pH.
• the solutions obtained can gel in the presence of the physiological medium or of a culture medium
• chitosan 2%, 1%, 0.75% and 0.5%) are prepared by diluting the solutions obtained in Example 1.
• a preparation of chitosan 2% (w / w) obtained in Example 1 (DA: 2, Mw: 450000 g.mol 1 BIOXIS SAS Pharmaceuticals) was diluted in a saline solution (NaCl 300 mOsmol. L "1 ) containing 1% (w / w) of acetic acid in a well (in 24-well plates) and then distributed on half of the other wells, dried, rinsed with PBS and then with the culture medium before seeding cell (line 3.
• phase contrast microscopy x20: the images are taken at different times (2 days and 5 days after seeding), at an identical position for each well
• Differentiation and storage of oleic acid are analyzed by fluorescence microscopy: the cells are fixed and then labeled with AdipoRed (green experimentally or as identified in the figures) highlighting the presence of fatty acids in the form of triglycerides (TG) stored in several droplets during differentiation, fusing into a single droplet when the adipocytes are mature) and with Hoechst 3352 (red in an experimental manner) for the labeling of nuclei.
• the labeling is observed by fluorescence microscopy and the quantification performed by imaging. Imaging and fluorescence quantification are performed on
• 3T3L1 cells Two days after inoculation, for all concentrations, 3T3L1 cells are able to proliferate and reach confluency in 5 days ( Figure 1A and 1B). Thus, at the concentrations tested, the adipocytes increase in number and in volume. The morphology of the cells, however, suggests an aggressive environment, even toxic for the 2% condition.
• Figure 2 shows the influence of chitosan concentration on oleic acid storage by 3T3L1 cells during adipocyte differentiation.
• oleic acid fatty acid that the adipocyte cells have the capacity to capture.
• AdipoRed labeling shows fatty acid accumulation when the cells are in the presence of 0.5, 0.75% and 1% chitosan with respect to conditions containing no chitosan.
• 3T3L1 cells capture more oleic acid than the witness. Quantification of this accumulation demonstrates that it is maximal when the cells are cultured in the presence of 0.5% chitosan (FIG. 2C).
• 3T3L1 cells are able to proliferate in the presence of chitosan. After two days in culture, the presence of chitosan seems to have a toxic effect on the 3T3L1 line for concentrations greater than or equal to 2%. Chitosan promotes the capture of fatty acids in a dose-dependent manner. Among the tested solutions, it seems that it is the solutions with 0.5% which present the best efficiency. This capture would allow an increase of the volume of the adipocytes and thus, by extrapolation, of the fatty tissue in vivo.
• a 2% (w / w) chitosan preparation obtained in Example 1 For this, a 2% (w / w) chitosan preparation (DA: 2%, Mw: 450000 g.mol -1 , BIOXIS Pharmaceuticals SAS)
• the solutions were used as is without pre-dilution in acidic saline solution and a solution based on Collagen I 2mg / ml + Fibronectin I 1mg / mL + Chitosan 2% (Noted Col FN Chi2) is also evaluated
• the compositions are distributed in 96-well plate after cell seeding (murine adipocyte line 3T3L1, ref ATCC CL-173 TM) When the cells are at confluence, the differentiation is induced by adding a medium The cells are then treated with a low dose of oleic acid (OA, 2.5 ⁇ l) for 6 hours The cells are put back in culture medium without oleic acid until the next day before observation on Cytation 3.
• FIG. 3 shows that the solution Collagen I 2 mg / ml + Fibronectin I 1 mg / ml + Chitosan at 2% (Noted Col FN Chi 2) has less adipocytes of size less than 15 ⁇ m and more adipocytes with a size of between 15 and 55 ⁇ as the chitosan solution at 2%.
• adding extracellular matrix compounds such as collagen or fibronectin therefore makes it possible to promote the increase in the number and the average size (and thus the volume) of the lipid droplets.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Dermatology (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Oral & Maxillofacial Surgery (AREA)
• Transplantation (AREA)
• Biomedical Technology (AREA)
• Zoology (AREA)
• Molecular Biology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Botany (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Birds (AREA)
• Dispersion Chemistry (AREA)
• Pain & Pain Management (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Gastroenterology & Hepatology (AREA)
• Immunology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Gerontology & Geriatric Medicine (AREA)
• Biophysics (AREA)
• Urology & Nephrology (AREA)
• Cardiology (AREA)
• Vascular Medicine (AREA)
• Heart & Thoracic Surgery (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Cosmetics (AREA)
• Materials For Medical Uses (AREA)
• Polysaccharides And Polysaccharide Derivatives (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=58009944

Family Applications (1)

Country Status (8)

Families Citing this family (2)

Family Cites Families (6)

• 2016
  • 2016-10-25 FR FR1660346A patent/FR3057778B1/fr active Active
• 2017
  • 2017-10-24 EP EP17804223.0A patent/EP3532113A1/fr not_active Withdrawn
  • 2017-10-24 CA CA3040778A patent/CA3040778A1/fr not_active Abandoned
  • 2017-10-24 CN CN201780063615.0A patent/CN109843345A/zh active Pending
  • 2017-10-24 WO PCT/FR2017/052933 patent/WO2018078277A1/fr unknown
  • 2017-10-24 KR KR1020197012537A patent/KR20190096946A/ko unknown
  • 2017-10-24 US US16/343,473 patent/US20190240379A1/en not_active Abandoned
  • 2017-10-24 BR BR112019008389A patent/BR112019008389A2/pt not_active Application Discontinuation

Also Published As

Similar Documents

Legal Events